TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis (MS). These data further elucidate VB-201’s mechanism of action and, for the first time, suggest an anti-inflammatory role of VB-201 in central nervous system (CNS) diseases including MS. The article appears in the September 14, 2010 issue of the journal.
